Eye fluid study sheds light on AMD treatment effects
NCT ID NCT07375901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 30 patients with a type of age-related macular degeneration (AMD) to see how treatment affects the barrier between blood and eye fluid. Researchers measured protein levels in the eye fluid before and during anti-angiogenic therapy. The goal was to better understand how the eye responds to treatment, not to test a new drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Filatov Institute of Eye Diseases and Tissue Therapy
Odesa, 65061, Ukraine
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily electric zap to the eye preserve sight in dry AMD?
- Can a new eye drug cut injection frequency for AMD patients?
- Should gene therapy be used for AMD? new study asks patients
- Scientists probe eye fluid to uncover why some macular degeneration patients Don't get better
- Can a stronger eylea dose dry up wet AMD faster?
- Gene therapy could end frequent eye injections for wet AMD